Screener
Tango Therapeutics TNGX Discovery Direct Program Expenses-RD — Research And Development Expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Tango Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Tango Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:15 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-221656
| Line item | Oncology Segment / Three Months Ended March 31, 2026 | Oncology Segment / Three Months Ended March 31, 2025 |
|---|---|---|
| TNG260 direct program expenses - R&D | 2,009 | 1,730 |
| TNG961 direct program expenses - R&D | 408 | 2,221 |
| TNG908 direct program expenses* - R&D | 581 | 1,712 |
| Discovery direct program expenses - R&D | 1,872 | 4,679 |
| Personnel-related expenses - R&D | 12,931 | 13,850 |
| Facilities and other related expenses - R&D | 4,338 | 5,465 |
| Other segment expenses (a) | 11,980 | 8,826 |
| Segment net loss | $(45,514) | $(39,876) |
Item 1. Financial Statements.
FAQ
- What is Tango Therapeutics's discovery direct program expenses-rd — research and development expense?
- Tango Therapeutics (TNGX) reported discovery direct program expenses-rd — research and development expense of $1.87M in Q1 2026.
- How has Tango Therapeutics's discovery direct program expenses-rd — research and development expense changed year-over-year?
- Tango Therapeutics's discovery direct program expenses-rd — research and development expense decreased by 60.0% year-over-year, from $4.68M to $1.87M.
- What is the long-term trend for Tango Therapeutics's discovery direct program expenses-rd — research and development expense?
- Over 3 years (2022 to 2025), Tango Therapeutics's discovery direct program expenses-rd — research and development expense has grown at a -29.3% compound annual growth rate (CAGR), from $28.76M to $10.17M.
- What does discovery direct program expenses-rd — research and development expense mean?
- This metric represents the direct research and development expenditures specifically allocated to the company's early-stage drug discovery programs. It captures the costs associated with identifying novel therapeutic targets and advancing preclinical candidates before they enter formal clinical development. Tracking these expenses provides insight into the company's investment intensity in its internal innovation pipeline and the sustainability of its long-term oncology research efforts.
Ask your AI about Tango Therapeutics's discovery direct program expenses-rd — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude